Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Fadi G. Haddad, Hagop M. Kantarjian, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey L. Jorgensen, Joseph E. Jabbour, Sa A. Wang, Yesid Alvarado Valero, Xuemei Wang, Alessandra Ferrajoli, Diane Habib, Jan A. Burger, Courtney D. DiNardo, Zena Komrokji, Lucia Masarova, Tapan M. Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Rebecca Garris, Elias Jabbour
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405038771